生物制剂在狼疮肾炎治疗中的应用  

Biologics in treatment of lupus nephritis

作　　者：杨文卓 王欣[1] 陈崴[1] 李志坚[1] Yang Wenzhuo;Wang Xin;Chen Wei;Li Zhijian(Department of Nephrology,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院肾内科,广州510080

出　　处：《中华肾脏病杂志》2023年第7期552-558,共7页Chinese Journal of Nephrology

基　　金：国家重点研发计划课题资助(2021YFC2501302);广东省肾脏病重点实验室(2020B1212060028);国家卫生健康委员会肾脏病临床研究重点实验室(2002B60118)。

摘　　要：系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种导致多种重要组织和靶器官损害的自身免疫性疾病,狼疮肾炎(lupus nephritis,LN)是SLE累及肾脏的严重并发症。在LN的治疗策略中,糖皮质激素和免疫抑制剂的使用一直占主导地位,同时其不良反应也引起人们的关注。近年来,生物制剂的研发与使用为LN的治疗提供了新思路,也在SLE和LN的多项临床试验中取得了肯定的疗效。生物制剂可以分为单克隆抗体类和融合蛋白类,它们通过多种细胞分子层面的机制对SLE和LN产生治疗作用。该文从生物制剂的不同作用机制角度,对其治疗SLE和LN的最近研究进展进行综述。Systemic lupus erythematosus(SLE)is an autoimmune disease that causes damage to multiple vital tissues and target organs,and lupus nephritis(LN)is a serious complication of SLE involving the kidneys.The use of glucocorticoids and immunosuppressants has been dominant in the treatment strategy of LN,while their adverse effects have also raised concerns.In recent years,the development and use of biologics have provided new ideas for the treatment of LN and have also achieved positive efficacy in several clinical trials in SLE and LN.Biologics can be divided into monoclonal antibodies and recombinant proteins,which exert therapeutic effects on SLE and LN through a variety of mechanisms at the cellular-molecular level.In this article,we review recent research advances in the treatment of SLE and LN from the perspective of the different mechanisms of action of biologics.

关 键 词：红斑狼疮 系统性 狼疮肾炎 生物因子 治疗学 

分 类 号：R593.242[医药卫生—内科学]